Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 18, 2026Journal for ImmunoTherapy of CancerOpen Access

CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors

View Full Paper
Ask AI
Bookmark
Share

Authors

BXBin XiaoSXSong XueYLYuwei Li

Discussion

Loading...

Member takes

Overview

Research demonstrates overcoming cancer vaccine resistance in advanced tumors by targeting PMN-MDSCs.

Key Points

  • This study aims to understand the mechanisms of vaccine resistance in advanced tumors and explore strategies to enhance vaccine efficacy.
  • Investigated vaccine efficacy in B16-OVA melanoma and TC-1 HPV cancer models.
  • Analyzed tumor microenvironment using flow cytometry and multi-analysis.
  • Assessed PMN-MDSC activity through surface marker staining and functional assays.
  • Employed CD300ld-knockout mice and recombinant proteins for CD300ld blockade in trials.
  • Tested different cancer vaccine formulations on humanized CD300ld mice.
  • Late-stage vaccination with PC7A nanovaccine showed minimal therapeutic effect on tumor progression.
  • Increased infiltration and immunosuppressive activity of PMN-MDSCs were observed.
  • CD300ld knockout mice showed abolished PMN-MDSC recruitment and restored vaccine efficacy.
  • Blockade of CD300ld with recombinant proteins overcame tumor resistance in multiple models.
  • PMN-MDSCs are identified as key mediators of vaccine resistance in advanced tumors.

Cite This Study

Xiao et al. (2026) studied this question.

synapsesocial.com/papers/696c785beb60fb80d139686dhttps://doi.org/10.1136/jitc-2025-013336
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting polymorphonuclear myeloid‐derived suppressor cells in the immunosuppressive tumor microenvironment for cancer immunotherapy2024
  2. 2Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy2024 · 3 citations
  3. 3Abstract 6751: <i>In situ</i> vaccination with <i>Flt3l</i> gene modified CD103+ type 1 conventional dendritic cells synergizes with anti-PD-1 checkpoint blockade in murine models of non-small cell lung cancer2024
  4. 4Cancer nanovaccine plus doxorubicin and immune checkpoint blockade overcomes chemoresistance and delays postsurgical recurrence2026
  5. 5In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 <sup>+</sup> T cell responses2025